Used primarily in cancer research, particularly for its potential in treating solid tumors and hematological malignancies. It functions as a potent inhibitor of PARP enzymes, which play a key role in DNA repair mechanisms. By blocking these enzymes, the compound enhances the effectiveness of DNA-damaging agents such as chemotherapy and radiation. It shows promise in cancers with deficiencies in DNA repair pathways, including those with BRCA mutations. Investigated in clinical trials for ovarian, breast, and prostate cancers, it is explored both as a monotherapy and in combination with other anticancer agents to improve treatment outcomes.